Understand the source comparison
Peptides for Fat Burning — Clinical Evidence Comparison
CJC-1295 + Ipamorelin GHRH + ghrelin receptor agonism → pulsatile GH 6–9% body fat reduction 45–60% above baseline High. Minimal effect without resistance training Gold standard for GH-mediated body recomposition; requires structured protocol Hexarelin Potent
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 + Ipamorelin
- GHRH + ghrelin receptor agonism → pulsatile GH
- 6–9% body fat reduction
- 45–60% above baseline
- High. Minimal effect without resistance training
- Gold standard for GH-mediated body recomposition; requires structured protocol
- Hexarelin
- Potent GHS-R1a agonism → acute GH spike
- 4–7% body fat reduction
- 50–80% above baseline (acute)
- Moderate. Some effect with diet alone
- Strong acute response but desensitizes after 4–8 weeks; cycling required
- MK-677
- Oral ghrelin mimetic → sustained GH elevation
- 3–5% fat mass reduction
- 30–50% above baseline
- Moderate. Works with caloric deficit
- Convenient oral dosing; less pronounced pulse control than injectables
- Tesofensine
- Triple monoamine reuptake inhibitor → appetite suppression + thermogenesis
- 8–12% total body weight
- No direct effect
- Low. Works independently of training
- Strongest independent weight loss signal; cardiovascular side effects limit use
- AOD-9604
- GH fragment → beta-3 adrenergic activation, HSL stimulation
- 0–3% fat mass reduction
- High. Ineffective without caloric deficit
- Mechanistically appealing but weak human efficacy data